Exelixis Looks to Next-Gen Cancer Drug as Cabometyx Underwhelms Again

[cafead]

via Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma and head-and-neck cancer, with several readouts slated for the second half of 2025.

article source